- Home
- SNTI vs LEE Comparison
SNTI vs LEE Comparison
Compare SNTI & LEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- LEE
- Stock Information
- Founded
- SNTI 2016
- LEE 1890
- Country
- SNTI United States
- LEE United States
- Employees
- SNTI N/A
- LEE N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- LEE Newspapers/Magazines
- Sector
- SNTI Health Care
- LEE Consumer Discretionary
- Exchange
- SNTI Nasdaq
- LEE Nasdaq
- Market Cap
- SNTI 39.6M
- LEE 42.1M
- IPO Year
- SNTI N/A
- LEE N/A
- Fundamental
- Price
- SNTI $1.56
- LEE $4.26
- Analyst Decision
- SNTI Strong Buy
- LEE
- Analyst Count
- SNTI 2
- LEE 0
- Target Price
- SNTI $8.50
- LEE N/A
- AVG Volume (30 Days)
- SNTI 107.2K
- LEE 34.4K
- Earning Date
- SNTI 08-07-2025
- LEE 08-07-2025
- Dividend Yield
- SNTI N/A
- LEE N/A
- EPS Growth
- SNTI N/A
- LEE N/A
- EPS
- SNTI N/A
- LEE N/A
- Revenue
- SNTI N/A
- LEE $581,809,000.00
- Revenue This Year
- SNTI N/A
- LEE N/A
- Revenue Next Year
- SNTI $150.00
- LEE N/A
- P/E Ratio
- SNTI N/A
- LEE N/A
- Revenue Growth
- SNTI N/A
- LEE N/A
- 52 Week Low
- SNTI $1.46
- LEE $3.79
- 52 Week High
- SNTI $16.94
- LEE $19.63
- Technical
- Relative Strength Index (RSI)
- SNTI 37.24
- LEE 40.87
- Support Level
- SNTI $1.52
- LEE $3.96
- Resistance Level
- SNTI $1.65
- LEE $4.43
- Average True Range (ATR)
- SNTI 0.10
- LEE 0.37
- MACD
- SNTI 0.03
- LEE 0.07
- Stochastic Oscillator
- SNTI 50.00
- LEE 54.65
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About LEE Lee Enterprises Incorporated
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.